Monitor stock price action around the $2.68 conversion price, which could act as a ceiling in the near term. The offering removes near-term bankruptcy risk but adds overhang from potential dilution. Watch for further clinical data readouts (OCU400 Phase 3 topline in Q1 2027) as catalysts.
Price Chart
Executive Summary
Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrangement revenue of $1.5M beat the $358K estimate. The company simultaneously priced $115M (upsized to $130M) of 6.75% convertible senior notes due 2034, with net proceeds of ~$99.5M used to repay $32.7M of high-cost Avenue debt and extend cash runway into 2028. The combination of an EPS miss and material convertible dilution tempers the positive clinical milestones.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.06 vs consensus -$0.05 (16.7% miss)
- Q1 2026 revenue $1.533M (mostly collaborative) vs consensus $358K (beat)
- Net loss widened to $19.2M from $15.4M YoY; operating expenses up 21%
- Priced $115M (option for +$15M) of 6.75% convertible senior notes due 2034
- Conversion price $2.68 (45% premium to $1.85 recent close); convertibility starts May 2027
- ~$32.7M of proceeds to repay Avenue debt (12.5% interest); cash runway extended into 2028
- Cash and equivalents pro forma ~$112M at closing (or $127M if all warrants exercised)
- Positive clinical updates: Phase 3 RP enrollment complete, Phase 2/3 Stargardt enrollment complete, Phase 2 GA data showing 31% lesion reduction
Financial Impact
EPS miss of $0.01 vs consensus; convertible notes represent ~18% of market cap dilution potential at conversion
Risk Factors
- Dilution from note conversion (up to ~42.9M shares if fully converted at initial rate)
- EPS miss indicates worsening cost trajectory; operating expenses rising faster than revenue
- Clinical trial risk: Phase 3 data for RP and Stargardt not yet available
- Revenue concentration in small collaborative arrangements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-055411 |
| Document: tm2613584d1_8k.htm | 0001104659-26-055411 |
| Document: tm2613584d1_ex99-2.htm | 0001104659-26-055411 |
| Document: tm2613584d1_ex99-3.htm | 0001104659-26-055411 |
| Document: 0001104659-26-055411-index-headers.html | 0001104659-26-055411 |
| Document: 0001104659-26-055411-index.html | 0001104659-26-055411 |
| Document: 0001104659-26-055411.txt | 0001104659-26-055411 |
| 8-K Data (Synthetic) | 0001104659-26-055411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | Press Release | $1.33 $1.05 | ▼ −21.05% | ▼ −22.23% | $1.02 (−23.31%) |
Jul 13, 2026 11w ago | 8-K | $1.41 $1.31 | ▼ −7.09% | ▼ −10.28% | $1.02 (−27.66%) |
Jun 11, 2026 16w ago | 8-K | $1.21 $1.47 | ▲ +21.49% | ▲ +19.71% | $1.02 (−15.70%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.22 $1.47 | ▲ +20.49% | ▲ +18.60% | $1.02 (−16.39%) |
May 5, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▲ +10.07% | ▲ +15.02% | $1.02 (+31.54%) |
May 4, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
Apr 29, 2026 22w ago | Press Release | $1.68 $1.38 | ▼ −17.86% | ▼ −23.32% | $1.02 (−39.29%) |
Mar 24, 2026 27w ago | Press Release | $1.92 $1.68 | ▼ −12.50% | ▼ −21.40% | $1.02 (−46.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access